The role of N-acetylcysteine and glutathione in the management of Parkinson’s disease: a systematic review of oxidative biomarkers and clinical outcomes

Resumen del estudio

improvements in symptoms or oxidative stress markers. The studies had limitations, including small sample sizes, short intervention durations, and inconsistencies in dosage and administration routes. These factors constrain the strength of the conclusions, and evidence for both NAC and GSH remains preliminary. Furthermore, while NAC shows promise as a neuroprotective intervention, findings for GSH are inconclusive. More large-scale, long-term randomised controlled trials are needed to validate these results and explore NAC and GSH's long-term therapeutic potential in managing PD.